On 24 May, a new chemical drug communication session was successfully held in Shenzhen, Guangdong Province, jointly hosted by the Centre for Drug Evaluation, NMPA and the Guangdong-Hong Kong-Macau Greater Bay Area Center for Drug Evaluation and Inspection of NMPA. About 300 participants, including representatives from Guangdong, Hong Kong and Macao Greater Bay Area drug regulatory authorities, pharmaceutical companies and R&D institutions, attended the meeting.

This training session invited Wang Yamin, Director of the Department of Chemical Pharmacy of the Drug Review Center, and three senior reviewers, Zhou Haohui, Liu Yonghui and Ma Chunhui, to give lectures and explain with case studies the contents of strengthening the communication and exchange of chemical new drug pharmacy and assisting the development of new drug innovation, and the communication and exchange of pharmacy before the application for new drug clinical trial (IND application), before the application for new drug phase Ⅲ clinical trial, and before the application for new drug listing (NDA application). and explained with specific cases. In the exchange and discussion session, the common problems and technical requirements encountered by enterprises in innovative drug R&D were also answered in detail.

After the meeting, the participants said that the training deepened the understanding of enterprises and R&D institutions on the clinical and marketing application of new chemical drugs, and the content was abundant and in place, which is conducive to better promoting the R&D and declaration of innovative chemical drugs in the Greater Bay Area, and boosting the high-quality development of the pharmaceutical industry in the Greater Bay Area.

Translated Excerpts from web article：https://www.cde.org.cn/main/newspic/view/106a4091cf17429363e426b5b6613da1